Why the study?
Does VEGF-angiopoietin-1 (VA1) improve ischemic limb perfusion with fewer side effects compared to VEGF in a mouse model?
Population
Mouse skeletal muscle (ischemic limb model)
Comparison
VEGF-angiopoietin-1 (VA1) transgene delivery vs VEGF (vascular endothelial growth factor)
Design
Preclinical
Authors
Loading...
VA1 merits further development for safer angiogenesis in ischemia; leaves open clinical translation to human peripheral artery disease.
Does VEGF-angiopoietin-1 (VA1) improve ischemic limb perfusion with fewer side effects compared to VEGF in a mouse model?
The VEGF-angiopoietin-1 chimera promotes effective therapeutic angiogenesis with reduced vessel leakiness and inflammation compared to VEGF in a preclinical model.
Anisimov et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: